OSI Pharmaceuticals 社の 2010 年定時株主総会において
当社が推薦する取締役候補者の選任提案について

　アステラス製薬株式会社（本社：東京、社長：野木森　雅郁、以下「アステラス製薬」）は、OSI Pharmaceuticals, Inc.（本社：米国ニューヨーク州メルビル、以下「OSI Pharmaceuticals 社」）の 2010 年定時株主総会において、独自の取締役候補者を推薦することを同社に通知しましたので、お知らせ致します。

　このたびの取締役候補者の推薦は、当社による買収提案を拒否し続けている OSI Pharmaceuticals 社の現取締役会に代わる選択肢を同社の株主に提供するために行うものです。全ての取締役候補者は、実績に裏打ちされた高い適格性を有しており、取締役に選任された場合には、当社の買収提案により OSI Pharmaceuticals 社株主が現金によって公正かつ最大限の価値を実現する機会について、OSI Pharmaceuticals 社株主の最善の利益を考え前向きに検討いただけるものと確信しています。

　なお、当社が推薦する取締役候補者は添付資料の通りです。

　2010 年 3 月 1 日付け当社プレスリリース「米国医薬品会社 OSI Pharmaceuticals 社に対する株式公開買付けの開始に関するお知らせ」に記載の通り、当社の米国持株子会社アステラス US ホールディング Inc.（本社：イリノイ州ディアフィールド）の 100％子会社 Ruby Acquisition, Inc.が、OSI Pharmaceuticals 社の普通株式を 1 株あたり現金 52 ドルで買い取る公開買付けを米国時間 3 月 2 日に開始しました。本公開買付けにおける買付価格は、OSI Pharmaceuticals 社株式の 2010 年 2 月 26 日の終値（37.02 ドル/株）に対して 40％、同日までの直近 3 ヶ月の終値の平均値（34.01 ドル/株）に対して 53％のプレミアムを加えた価格となります。

　本件については、現地時間 3 月 16 日に米国において対外発表されています。

以　上

○ 当社が推薦する取締役候補者（10名）について

Martin Edelshain served as an executive for Gen-Probe Inc., a molecular diagnostics company, and its former parent, Chugai Pharmaceutical Co., Ltd, from 1995 to 2008.   Mr. Edelshain was instrumental in forming the 2002 strategic alliance between Chugai Pharma and Roche.

Cono R. Fusco spent 34 years as a partner at Grant Thornton LLP, one of the top global accounting firms. His career spanned virtually all aspects of the firm's operations, including client service, office, regional and national managing partner positions,   National Leadership Team, and Partnership Board member.

Michael A. Griffith was the founder and CEO of Aptuit Inc., a leading global pharmaceutical contract research, development and manufacturing company until 2008. In 2002, he was appointed Chairman of the Executive Committee of Centrue Financial Corporation.

Jill Kanin-Lovers has served on the Board of Alpharma Inc., a specialty pharmaceutical firm, First Advantage, a leading risk mitigation and business solutions provider and Heidrick & Struggles International Inc.

Jack Kaye has served as an independent director for Keryx Biopharmaceuticals Inc., Tongli Pharmaceuticals (USA), Inc. and Balboa Biosciences, Inc. From 1978 until May 2006, Mr. Kaye was a partner at Deloitte & Touche LLP.

Douglas E. Linton has served on the board of Bradley Pharmaceuticals and as vice president of Cardinal Health Inc. He was an Executive Advisor at Campbell Alliance Group, a management consultant that specializes in pharmaceuticals and biotech until 2009.

Timothy P. Lynch is a General Partner of Stonepine Capital, L.P., a partnership focused on investing in public, small-cap biotech and pharmaceutical companies.   He serves on the strategic advisory board of the Cowen Healthcare Royalty Fund and on the boards of Allos Therapeutics, Inc., Insite Vision Inc., and Nabi Biopharmaceuticals and is the former Chief Financial Officer of Tercica, Inc.

Jonathan R. Macey serves as the Sam Harris Professor of Corporate Law, Corporate Finance and Securities Law at Yale University and is a Professor at the Yale School of Management. He is a member of the National Adjudicatory Council of the Financial Industry Regulatory Association ("FINRA") and until 2009 served as a director on the board of WCI Communities, Inc.

Heidi L. Steiger is an Advisory Director at Berkshire Capital Securities LLC, an investment banking and strategic advisory boutique. From 2005 to the present, Ms. Steiger served as the Managing Partner at Topridge Associates LLC, a privately held consultant agency she founded. She also serves on the corporate board of Aviva USA and was a member of the Executive Management Committee at Neuberger Berman until 2004.

Joseph L. Turner currently sits on the boards of QLT Inc., ApopLogic Pharmaceuticals, Inc., Kythera Biopharmaceuticals, Inc., Sequel Pharmaceuticals, Inc. and Swarthmore College.   He has served as Chief Financial Officer of Myogen, Inc. and Centaur Pharmaceuticals.

以上